Kusterdingen

This research aims to evaluate the effect of a 24-week treatment with Treprostinil Palmitil Inhalation Powder (TPIP) compared to placebo on exercise capacity in adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD). This is a Phase 3, randomized, double-blind, placebo-controlled study involving participants diagnosed with PH WHO Group 3 linked to fibrotic interstitial lung disease. Participants will receive either TPIP or a placebo through oral inhalation using a capsule-based dry powder inhaler device once daily for 24 weeks. The study compares the impact of these treatments on exercise ability over the treatment duration. During the study, participants' exercise capacity will be assessed by changes in the 6-minute walk distance from baseline to week 24. Researchers will monitor safety and effectiveness through regular evaluations, including lung function tests, heart catheterization results, and walking tests to measure endurance and functional status. The total participation duration includes the 24-week treatment period with assessments at baseline and week 24.